AtriCure to Participate at the Morgan Stanley 18th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--Sep. 1, 2020-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18^th Annual Global Healthcare Conference being held virtually.

AtriCure’s management is scheduled to present on Monday, September 14, 2020, at 2:15 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip^® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005362/en/

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
[email protected]

Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
[email protected]

Source: AtriCure, Inc.